Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | ABL2 | P42684 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TLR4 | O00206 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | GALR2 | O43603 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | VCP | P55072 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077034 | 1.00 | FBP1 (1.00) | FBP1EGFRABL1ABL2ALDH1A1 | |
| SCHEMBL6910815 | 0.89 | FBP1 (0.78) | FBP1EGFRABL1ABL2ALDH1A1 | |
| SCHEMBL6910818 | 0.89 | FBP1 (0.78) | FBP1EGFRABL1ABL2ALDH1A1 | |
| SCHEMBL28838361 | 0.81 | TYR (0.69) | FBP1EGFRABL1ABL2ALDH1A1 | |
| SCHEMBL3667077 | 0.79 | EGFR (0.93) | FBP1EGFRABL1ABL2ALDH1A1 | |
| SCHEMBL3667079 | 0.79 | EGFR (0.93) | FBP1EGFRABL1ABL2ALDH1A1 | |
| SCHEMBL421633 | 0.78 | FBP1 (0.64) | FBP1EGFRABL1ABL2ALDH1A1 | |
| SCHEMBL102630 | 0.78 | FBP1 (1.00) | FBP1EGFRABL1ABL2ALDH1A1 | |
| SCHEMBL1681205 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL366122 | 0.78 | FBP1 (1.00) | FBP1EGFRABL1ABL2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-111655665-B | Nitroolefin non-steroidal anti-inflammatory drugs (NA-NSAIDS) and methods of treating inflammation-related disorders | 蒙得维的亚巴斯德研究所 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3732162-B1 | NITROALKENE NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NA-NSAIDS) AND METHODS OF TREATING INFLAMMATION RELATED CONDITIONS | INST PASTEUR DE MONTEVIDEO (UY) | 2024-03-06 | — | — | EP | disclosed |
| US-20210107860-A1 | NITROALKENE NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NA-NSAIDS) AND METHODS OF TREATING INFLAMMATION RELATED CONDITIONS | INSTITUT PASTEUR DE MONTEVIDEO (UY) | 2021-04-15 | — | — | US | disclosed |
| US-20210107860-A1 | NITROALKENE NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NA-NSAIDS) AND METHODS OF TREATING INFLAMMATION RELATED CONDITIONS | INSTITUT PASTEUR DE MONTEVIDEO (UY) | 2021-04-15 | — | — | US | disclosed |
| EP-3003301-B1 | NOVEL SUICIDAL LSD1 INHIBITORS TARGETING SOX2-EXPRESSING CANCER CELLS | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA LAS VEGAS (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3003301-B1 | NOVEL SUICIDAL LSD1 INHIBITORS TARGETING SOX2-EXPRESSING CANCER CELLS | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA LAS VEGAS (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10906864-B2 | Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDS) and methods of treating inflammation related conditions | INSTITUT PASTEUR DE MONTEVIDEO (UY) | 2021-02-02 | — | — | US | disclosed |
| EP-1526128-B1 | Process the preparation of alpha-hydroxycarboxylic acid amides | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1444195-B1 | PROCESS FOR THE PREPARATION OF ALPHA-HYDROXYCARBOXYLIC ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1526128-A2 | Process the preparation of alpha-hydroxycarboxylic acid amides | Syngenta Participations AG (CH) | 2005-04-27 | — | — | EP | disclosed |
| US-20050014950-A1 | Process for the preparation of alpha hydroxycarboxylic acid amides | SYNGENTA CROP PROTECTION, INC. | 2005-01-20 | — | — | US | disclosed |
| EP-1444195-A2 | PROCESS FOR THE PREPARATION OF ALPHA-HYDROXYCARBOXYLIC ACID AMIDES | Syngenta Participations AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004046081-A1 | BETA-NITROSTYRENE COMPOUND AND TELOMERASE INHIBITOR HAVING AN ANTICANCER ACTIVITY | DNA LINK, INC. (KR) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003042166-A2 | PROCESS FOR PREPARATION OF α-HYDROXYCARBOXYLIC ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014950-A1 | Process for the preparation of alpha hydroxycarboxylic acid amides | HCAR1, HCAR3, HCAR2 | FBP1 4377/4885EGFR 2127/4885ABL1 1820/4885 |
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | FBP1 1093/4885EGFR 4700/4885ABL1 2519/4885 |
| US-20210107860-A1 | NITROALKENE NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NA-NSAIDS) AND METHODS OF TREATING INFLAMMATION RELATED CONDITIONS | PTGES, PTGS1, PTGIS | FBP1 4354/4885EGFR 4079/4885ABL1 2877/4885 |
| US-10906864-B2 | Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDS) and methods of treating inflammation related conditions | PTGES, PTGS1, PTGIS | FBP1 4354/4885EGFR 4079/4885ABL1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.